210 related articles for article (PubMed ID: 23087817)
21. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U
J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose.
LaTemple DC; Henion TR; Anaraki F; Galili U
Cancer Res; 1996 Jul; 56(13):3069-74. PubMed ID: 8674064
[TBL] [Abstract][Full Text] [Related]
23. Cancer immunotherapy by intratumoral injection of α-gal glycolipids.
Whalen GF; Sullivan M; Piperdi B; Wasseff W; Galili U
Anticancer Res; 2012 Sep; 32(9):3861-8. PubMed ID: 22993330
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris.
Chen ZC; Tanemura M; Galili U
Glycobiology; 2001 Jul; 11(7):577-86. PubMed ID: 11447137
[TBL] [Abstract][Full Text] [Related]
25. alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli.
Galili U; Anaraki F
Glycobiology; 1995 Dec; 5(8):775-82. PubMed ID: 8720075
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
27. Avoiding detrimental human immune response against Mammalian extracellular matrix implants.
Galili U
Tissue Eng Part B Rev; 2015 Apr; 21(2):231-41. PubMed ID: 25315097
[TBL] [Abstract][Full Text] [Related]
28. Rapid recruitment and activation of macrophages by anti-Gal/α-Gal liposome interaction accelerates wound healing.
Wigglesworth KM; Racki WJ; Mishra R; Szomolanyi-Tsuda E; Greiner DL; Galili U
J Immunol; 2011 Apr; 186(7):4422-32. PubMed ID: 21357545
[TBL] [Abstract][Full Text] [Related]
29. Acceleration of wound healing by α-gal nanoparticles interacting with the natural anti-Gal antibody.
Galili U
J Immunol Res; 2015; 2015():589648. PubMed ID: 25922849
[TBL] [Abstract][Full Text] [Related]
30. Anti-alpha-galactosyl antibodies recognizing epitopes terminating with alpha1,4-linked galactose: human natural and mouse monoclonal anti-NOR and anti-P1 antibodies.
Duk M; Kusnierz-Alejska G; Korchagina EY; Bovin NV; Bochenek S; Lisowska E
Glycobiology; 2005 Feb; 15(2):109-18. PubMed ID: 15342552
[TBL] [Abstract][Full Text] [Related]
31. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.
Abdel-Motal UM; Wigglesworth K; Galili U
Vaccine; 2009 May; 27(23):3072-82. PubMed ID: 19428921
[TBL] [Abstract][Full Text] [Related]
32. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
33. Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Galili U; Chen ZC; Manches O; Plumas J; Preisler H
J Hematother Stem Cell Res; 2001 Aug; 10(4):501-11. PubMed ID: 11522233
[TBL] [Abstract][Full Text] [Related]
34. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay.
Ogawa H; Galili U
Glycoconj J; 2006 Dec; 23(9):663-74. PubMed ID: 17115279
[TBL] [Abstract][Full Text] [Related]
35. α-Gal Nanoparticles Mediated Homing of Endogenous Stem Cells for Repair and Regeneration of External and Internal Injuries by Localized Complement Activation and Macrophage Recruitment.
Galili U; Goldufsky JW; Schaer GL
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232789
[TBL] [Abstract][Full Text] [Related]
36. Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation.
Tanemura M; Yin D; Chong AS; Galili U
J Clin Invest; 2000 Feb; 105(3):301-10. PubMed ID: 10675356
[TBL] [Abstract][Full Text] [Related]
37. Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction.
Galili U; Wigglesworth K; Abdel-Motal UM
Burns; 2010 Mar; 36(2):239-51. PubMed ID: 19501971
[TBL] [Abstract][Full Text] [Related]
38. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen, II: tolerance induction on memory B cells.
Mohiuddin MM; Ogawa H; Yin DP; Galili U
Blood; 2003 Jul; 102(1):229-36. PubMed ID: 12649147
[TBL] [Abstract][Full Text] [Related]
39. Anti-gal A/B, a novel anti-blood group antibody identified in recipients of abo-incompatible kidney allografts.
Galili U; Ishida H; Tanabe K; Toma H
Transplantation; 2002 Dec; 74(11):1574-80. PubMed ID: 12490791
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Burn Healing in a Mouse Experimental Model Using α-Gal Nanoparticles.
Galili U
Bioengineering (Basel); 2023 Oct; 10(10):. PubMed ID: 37892895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
